If I had $20,000 to invest in ASX growth shares this month, I’d continue to focus on businesses with strong structural tailwinds, scalable models, and the potential to grow earnings meaningfully over the next five to ten years.
Importantly, I’d also spread that $20,000 across multiple ideas rather than betting everything on a single stock.
Here’s where I would look.
Xero Ltd (ASX: XRO)
Xero remains one of the highest-quality software businesses on the ASX, in my opinion.
It operates in a large and still underpenetrated global market for small business accounting software. With strong recurring revenue, improving margins, and ongoing expansion into North America and other international markets, Xero has a long runway for growth.
Software businesses with subscription revenue and high switching costs can become powerful long-term compounders. While Xero’s share price can be volatile, I think its structural positioning makes it a compelling growth holding.
If I were allocating the $20,000 today, I’d consider placing around $7,000 into Xero shares as a core global growth exposure.
Pro Medicus Ltd (ASX: PME)
Pro Medicus is another standout growth story.
The company provides imaging software to hospitals and healthcare networks, particularly in the United States. It has built a reputation for high-quality products, long-term contracts, and strong margins.
While some investors have expressed concerns about potential AI disruption, management has consistently indicated that it views AI as an opportunity to enhance its platform rather than a threat. Given its track record of winning large contracts and expanding its installed base, I think the long-term growth story remains intact.
I would consider allocating around $6,000 here, accepting short-term volatility in exchange for long-term upside potential.
Life360 Inc. (ASX: 360)
Life360 is another ASX growth share I’d look at buying.
It operates a global family safety app ecosystem with a large and growing user base. As the company scales, there is significant operating leverage potential, particularly as subscription revenue grows and new monetisation features are introduced.
This is not a low-risk stock, but for a growth-focused portion of a portfolio, I like its global opportunity and expanding product ecosystem.
For a $20,000 allocation, I might place around $4,000 into Life360, recognising that it could be more volatile than the other names.
Codan Ltd (ASX: CDA)
To round things out, I would add Codan.
Codan benefits from strong demand for its metal detection products, particularly when gold prices are elevated, and also has exposure to communications equipment and drone-related technology through its Domo Tactical Communications business.
It combines cyclical tailwinds with structural growth in security and defence-related markets. That mix gives it a slightly different growth profile compared to pure software names.
I would consider allocating the remaining $3,000 to this ASX growth share.
Why this mix of ASX growth shares works for me
This portfolio spreads $20,000 across four different growth themes: global software, healthcare technology, consumer app ecosystems, and industrial and defence-linked growth.
It avoids concentration in a single sector and balances higher-quality compounders with slightly more aggressive opportunities.
Growth investing always involves risk. Earnings can disappoint. Multiples can compress. Market sentiment can shift quickly.
But by focusing on businesses with scalable models, strong competitive positions, and long-term tailwinds, I think this type of portfolio gives a solid chance of outperforming over time.
The post Where to invest $20,000 in ASX growth shares this month appeared first on The Motley Fool Australia.
Should you invest $1,000 in Life360 right now?
Before you buy Life360 shares, consider this:
Motley Fool investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and Life360 wasn’t one of them.
The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.*
And right now, Scott thinks there are 5 stocks that may be better buys…
* Returns as of 20 Feb 2026
.custom-cta-button p {
margin-bottom: 0 !important;
}
More reading
- What are analysts saying about CAR, Wesfarmers, and Xero shares?
- These ASX 200 shares sank 20% or more in February
- Diversification: Why earnings geography matters more than company location
- How to make $25,000 of passive income a year
- 3 Australian growth stocks to buy in 2026
Motley Fool contributor Grace Alvino has positions in Codan. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Life360 and Xero. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has recommended Pro Medicus. The Motley Fool Australia has positions in and has recommended Life360 and Xero. The Motley Fool Australia has recommended Pro Medicus. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.